PMID- 28288884
OWN - NLM
STAT- MEDLINE
DCOM- 20171212
LR  - 20171212
IS  - 1615-5947 (Electronic)
IS  - 0890-5096 (Linking)
VI  - 43
DP  - 2017 Aug
TI  - The Profile of Circulating Matrix Metalloproteinases in Patients Undergoing Lower 
      Limb Endovascular Interventions for Peripheral Arterial Disease.
PG  - 188-196
LID - S0890-5096(17)30385-0 [pii]
LID - 10.1016/j.avsg.2016.11.010 [doi]
AB  - BACKGROUND: Matrix metalloproteinases (MMPs) play a significant role in the 
      development and progression of atherosclerotic vascular disease. We aimed to 
      document the profile of circulating MMPs in peripheral arterial disease (PAD) 
      patients undergoing lower limb endovascular revascularization. METHODS: A total 
      of 46 patients (37 male; mean age 66 +/- 11 years) undergoing elective lower limb 
      percutaneous revascularization (angioplasty/stent) for symptomatic PAD were 
      recruited from 2 vascular centers. Exclusion criteria were: acute limb ischemia, 
      active infection and/or wet gangrene, liver disease, end-stage renal disease, and 
      cancer. Patients having open revascularization or hybrid (open combined with 
      endovascular) procedures were also excluded. Peripheral venous blood samples were 
      taken on admission and 24 hrs after the procedure. Levels of MMP-2, MMP-3, MMP-7, 
      and MMP-9 were measured along with tissue inhibitors of MMPs (TIMPs) 1 and 2. 
      RESULTS: Compared to baseline values, there was a significant elevation in serum 
      MMP-3 (P = 0.014) and MMP-7 (P = 0.008) levels, whereas serum MMP-9 showed a 
      nonsignificant trend to increase (P = 0.169). On the other hand, no significant 
      alterations were found 24 hrs after angioplasty/stenting with regard to the MMP-2 
      level and TIMP-1 and 2 levels. CONCLUSIONS: This study documented the 
      periprocedural profile of circulating MMPs in patients undergoing 
      angioplasty/stenting for PAD. The implications of increased MMP-3 and MMP-7 
      activity after peripheral endovascular interventions and their potential clinical 
      relevance require further investigation.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Giagtzidis, Ioakeim T
AU  - Giagtzidis IT
AD  - The Fifth Department of Surgery, Aristotle University of Thessaloniki, 
      Thessaloniki, Greece.
FAU - Kadoglou, Nikolaos P
AU  - Kadoglou NP
AD  - Department of Vascular Surgery, "Attikon" University Hospital, University of 
      Athens, Athens, Greece.
FAU - Mantas, George
AU  - Mantas G
AD  - Department of Vascular Surgery, "Attikon" University Hospital, University of 
      Athens, Athens, Greece.
FAU - Spathis, Aris
AU  - Spathis A
AD  - Department of Cytopathology, "Attikon" University Hospital, Athens, Greece.
FAU - Papazoglou, Konstantinos O
AU  - Papazoglou KO
AD  - The Fifth Department of Surgery, Aristotle University of Thessaloniki, 
      Thessaloniki, Greece.
FAU - Karakitsos, Petros
AU  - Karakitsos P
AD  - Department of Cytopathology, "Attikon" University Hospital, Athens, Greece.
FAU - Liapis, Christos D
AU  - Liapis CD
AD  - Department of Vascular Surgery, "Attikon" University Hospital, University of 
      Athens, Athens, Greece.
FAU - Karkos, Christos D
AU  - Karkos CD
AD  - The Fifth Department of Surgery, Aristotle University of Thessaloniki, 
      Thessaloniki, Greece. Electronic address: ckarkos@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20170311
PL  - Netherlands
TA  - Ann Vasc Surg
JT  - Annals of vascular surgery
JID - 8703941
RN  - 0 (TIMP1 protein, human)
RN  - 0 (TIMP2 protein, human)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - EC 3.4.24.23 (MMP7 protein, human)
RN  - EC 3.4.24.23 (Matrix Metalloproteinase 7)
RN  - EC 3.4.24.24 (MMP2 protein, human)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Angioplasty/instrumentation
MH  - Female
MH  - Greece
MH  - Humans
MH  - Lower Extremity/*blood supply
MH  - Male
MH  - Matrix Metalloproteinase 2/blood
MH  - Matrix Metalloproteinase 3/blood
MH  - Matrix Metalloproteinase 7/blood
MH  - Matrix Metalloproteinase 9/blood
MH  - Matrix Metalloproteinases/*blood
MH  - Middle Aged
MH  - Peripheral Arterial Disease/blood/diagnostic imaging/enzymology/*therapy
MH  - Prospective Studies
MH  - Stents
MH  - Time Factors
MH  - Tissue Inhibitor of Metalloproteinase-1/blood
MH  - Tissue Inhibitor of Metalloproteinase-2/blood
MH  - Treatment Outcome
EDAT- 2017/03/16 06:00
MHDA- 2017/12/13 06:00
CRDT- 2017/03/15 06:00
PHST- 2016/07/28 00:00 [received]
PHST- 2016/11/02 00:00 [revised]
PHST- 2016/11/04 00:00 [accepted]
PHST- 2017/03/16 06:00 [pubmed]
PHST- 2017/12/13 06:00 [medline]
PHST- 2017/03/15 06:00 [entrez]
AID - S0890-5096(17)30385-0 [pii]
AID - 10.1016/j.avsg.2016.11.010 [doi]
PST - ppublish
SO  - Ann Vasc Surg. 2017 Aug;43:188-196. doi: 10.1016/j.avsg.2016.11.010. Epub 2017 
      Mar 11.